Search the Newsreel

Renaissance Technologies LLC Takes Position in Deluxe Corporation $DLX

Renaissance Technologies LLC has acquired a new position in Deluxe Corporation (NYSE:DLX), purchasing 51,230 shares valued at approximately $1.41 million, representing a 0.11% stake in the company. Deluxe reported stronger-than-expected quarterly earnings and revenue, though revenue declined year-over-year. The company also declared a quarterly …

Hennion & Walsh Asset Management Inc. Invests $1.24 Million in Lexeo Therapeutics, Inc. $LXEO

Hennion & Walsh Asset Management Inc. has initiated a new position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO), purchasing 265,697 shares valued at approximately $1.24 million during the second quarter. This investment comes as institutional investors collectively own 60.67% of the company. Lexeo Therapeutics recently reported …

Exelixis (EXEL) Q2 2026 Earnings Call Transcript

Exelixis (EXEL) reported its Q2 2026 earnings, with total revenues reaching $628.7 million, a 10.6% increase year-over-year, driven by cabozantinib sales. The company updated its full-year 2026 revenue guidance downwards due to a more gradual sales ramp in the neuroendocrine tumor indication but reduced …

Annex Advisory Services LLC Makes New Investment in Exelixis, Inc. $EXEL

Annex Advisory Services LLC has acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL), purchasing 25,918 shares valued at approximately $1.41 million during the second quarter. This investment comes as Exelixis reported strong quarterly earnings, surpassing EPS expectations, though revenue slightly missed analyst estimates. Despite …

Bank of America Corp DE Boosts Stake in MarketAxess Holdings Inc. $MKTX

Bank of America Corp DE has increased its stake in MarketAxess Holdings Inc. by 32.4% during the first quarter, now owning 263,858 shares valued at $43.53 million. This comes as other institutional investors have also adjusted their positions in the financial services provider. MarketAxess …

Exelon Corp (EXC) Earnings Forecast: Future EPS & Revenue Growth Estimates

MarketAxess Holdings Inc. (NASDAQ:MKTX) Receives Average Rating of "Hold" from Brokerages

MarketAxess Holdings Inc. (NASDAQ:MKTX) has received a consensus "Hold" rating from thirteen brokerages, with an average 12-month price target of $156.10. Despite this, the company exceeded quarterly earnings expectations with an adjusted EPS of $1.95 and declared a quarterly dividend of $0.78 per share, …

How Investors May Respond To Exelon (EXC) Balancing Storm Recovery Costs With Steady Utility Earnings

Exelixis, Inc. (EXEL) Stock Forecasts

Argus has lowered its target price for Exelixis Inc. (EXEL) to $56.00, while the current price stands at $50.44. Exelixis is a biopharmaceutical company focused on discovering, developing, and commercializing cancer treatments.

Nexxen International Ltd. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:NEXN) 2026-08-12

Nexxen International (NEXN) reported record second-quarter results, driven by strong growth in connected television, mobile, and data products. The company exceeded consensus estimates and raised its full-year outlook for contribution ex-TAC and programmatic revenue, attributing success to investments in its integrated platform, AI capabilities, …

Ares entities (NASDAQ: XE) disclose 38.3M-share, 12.3% holding in X-Energy

A group of Ares-affiliated entities has filed a Schedule 13G, reporting a 12.3% beneficial ownership stake in X-Energy, Inc. (NASDAQ: XE). This holding amounts to 38,263,341 Class A shares, including those convertible from Common Units. The filing details the individual holdings of various Ares …

NEXN Stock Price and Chart — NASDAQ:NEXN

This article provides a detailed overview of Nexxen International Ltd. (NEXN) stock, including its current price, market capitalization, financial performance, and analyst ratings. It highlights key statistics such as revenue and EPS, recent earnings reports, and future forecasts, along with a list of ETFs …

Exelixis director Mary Beckerle sells $526k in shares

Exelixis director Mary Beckerle sold 9,812 shares of the company's common stock for over $526,000, executed under a Rule 10b5-1 trading plan. This transaction leaves her with 16,079 beneficially owned shares, including RSUs. The sale occurred as Exelixis's stock saw a recent decline but …

Insider Selling: Exelixis (NASDAQ:EXEL) Director Sells $526,511.92 in Stock

Exelixis (NASDAQ:EXEL) Director Mary Beckerle sold 9,812 shares of company stock, valued at $526,511.92, under a pre-arranged Rule 10b5-1 trading plan. This transaction reduced her ownership by 37.9% to 16,079 shares. The biotechnology company recently reported strong quarterly earnings, beating analyst estimates with $0.91 …

Exelixis (EXEL) director Beckerle sells 9,812 shares via Rule 10b5-1 plan

Exelixis director Mary C. Beckerle sold 9,812 shares of common stock on August 10, 2026, at a weighted average price of $53.66 per share, under a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Beckerle's holdings consist of 16,079 shares, which are to be …

PIXELWORKS, INC 2026: Revenue $64K, EPS ($0.44) — 10-Q Summary

PIXELWORKS, INC (PXLW) reported its first-quarter 2026 results, showing a significant strategic shift after selling its semiconductor business to focus on cinematic visualization. The company generated $64K in revenue primarily from services and licensing, with a net loss of ($2.8M) and diluted EPS of …

Xeris Biopharma (XERS) insider Steven Pieper plans Rule 144 sale of 20,000 shares

Xeris Biopharma insider Steven Pieper has filed to sell 20,000 common shares under Rule 144, with an aggregate market value of $167,800.00, to be handled by Morgan Stanley Smith Barney LLC. These shares originated from Restricted Stock Units granted in January 2025. This planned …

Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results, Hits Estimates

Lexeo Therapeutics (NASDAQ:LXEO) announced its latest quarterly earnings, reporting a loss of $0.30 per share, which matched analysts' consensus estimates. Following the announcement, the stock saw a 4.6% increase to $5.00, although it remains significantly below its 12-month high. Analysts maintain a "Buy" rating …

Nexxen International (NASDAQ:NEXN) Price Target Raised to $13.00 at Needham & Company LLC

Needham & Company LLC has increased its price target for Nexxen International (NASDAQ:NEXN) to $13.00 from $10.50, maintaining a "buy" rating and indicating a potential upside of 24.05%. This follows Nexxen exceeding its Q2 earnings and revenue expectations, with the company reporting $0.23 EPS …

Nexxen International (NASDAQ:NEXN) Issues Quarterly Earnings Results

Nexxen International Q2 Earnings Call Highlights

Key Points Interested in Nexxen International Ltd. Sponsored ADR? Here are five stocks we like better. Record Q2 performance: Contribution ex-TAC rose 11% year over year to $97.8 million, while programmatic revenue increased 12% to $95.2 million. CTV revenue jumped 33% to a record …

Lexeo Therapeutics, Inc. (LXEO) Stock Price, News, Quote & History

Earnings call transcript: Nexxen lifts 2026 outlook after record Q2 growth

Nexxen International Ltd. reported record second-quarter results with double-digit growth in contribution ex-TAC and programmatic revenue, leading management to raise its full-year 2026 revenue guidance for the third time this year. Despite a slight dip in non-IFRS diluted earnings per share due to increased …

Nexxen International Ltd reports results for the quarter ended June 30 - Earnings Summary

Nexxen International Ltd has reported its financial results for the quarter that ended on June 30. This brief summary indicates the availability of the earnings report. The full article content is behind a paywall, requiring a subscription to TradingView to access.

Nexxen International (NASDAQ: NEXN) lifts 2026 outlook after record Q2 CTV growth

Form 8K Lexeo Therapeutics Inc For: 12 August By Investing.com

The article reports that Lexeo Therapeutics Inc. filed a Form 8K on August 12. It briefly mentions the company name and filing date, without providing further details on the content of the filing. The article is very short and seems to act as a …

Lexeo Therapeutics, Inc. 2Q 2026: Net loss $25.9M, EPS $(0.30) — 10-Q Summary

Lexeo Therapeutics, Inc. reported a net loss of $25.9 million and an EPS of $(0.30) for the second quarter of 2026, remaining pre-revenue. The company highlighted clinical progress for LX2006 and LX2020, including the initiation of a pivotal trial for LX2006 and RMAT designation …

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

Lexeo Therapeutics announced its second quarter 2026 financial results and operational highlights, focusing on advancements in its gene therapy pipeline. Key achievements include the initiation of the pivotal SUNRISE-FA 2 trial for LX2006 in Friedreich ataxia cardiomyopathy and the FDA's RMAT designation for LX2020 …

LXEO: Gene therapies for rare cardiac diseases advance with strong data, pipeline, and financial runway

Lexeo Therapeutics (LXEO) is focused on gene therapies for rare cardiac diseases, with a pipeline that includes two clinical-stage and two preclinical programs. Its lead candidates, LX2006 and LX2020, are showing promising efficacy and safety data, with key milestones anticipated. The company reports strong …

Lexeo Therapeutics advances gene therapy and gains RMAT status

Three Nexxen Executives Take New Roles Across Its Ad Platform

Nexxen (NASDAQ: NEXN) has announced key executive appointments to drive the next phase of growth for its unified, AI-driven advertising platform. Chance Johnson is now President, Kara Puccinelli is Chief Commercial Officer, and Kenneth Suh is Chief Business Officer. These changes aim to strengthen …

AQR Capital discloses 11.0M-share Exelixis (EXEL) position at 4.39% ownership

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have disclosed a beneficial ownership of 11,023,943 shares of Exelixis, Inc. common stock, representing 4.39% of the class. The filing indicates shared voting power over 10,935,221 shares and shared dispositive power over all 11,023,943 …

Lexeo Therapeutics (LXEO) narrows loss and ends H1 2026 with $234M cash

MarketAxess (NASDAQ:MKTX) Rating Lowered to Hold at Keefe, Bruyette & Woods

Keefe, Bruyette & Woods downgraded MarketAxess (NASDAQ:MKTX) from "moderate buy" to "hold," aligning with a broader analyst consensus of "Hold" and an average price target of $156.10. Despite the downgrade, MarketAxess recently exceeded quarterly earnings expectations, reporting EPS of $1.95 against an estimate of …

We Think Crexendo's (NASDAQ:CXDO) Profit Is Only A Baseline For What They Can Achieve

Crexendo, Inc. (NASDAQ:CXDO) recently posted solid earnings, but the market appears to be overly pessimistic. Analysis shows that the company's statutory earnings are likely conservative due to a negative accrual ratio and the impact of unusual items. However, shareholder dilution from new share issuance …

Pixelworks Inc (PXLW) Stock News Today

This article provides recent news and financial updates for Pixelworks Inc (PXLW). It highlights the company's Q2 2026 earnings report, noting a decline in revenue and a widening operating loss. The page also displays current stock metrics and links to various financial data points …